Risultati di ricerca - Portale di modelli di dati medici (MDM-Portal)

Filtra i risultati della ricerca
Seleziona modelli di dati

Modelli di dati selezionati

Devi effettuare il log in per selezionare i modelli di dati da scaricare per successive analisi

37 Risultati di ricerca.

DASS Depressions-Angst-Stress-Skalen – deutschsprachige Kurzfassung - DASS

- 28/12/21 - 1 modulo, 1 ItemGroup, 21 elementi, 1 linguaggio

ItemGroup: Fragen zum Befinden

Die deutschsprachige Kurzfassung der Depressions-Angst-Stress-Skalen (DASS) wird in der Schmerzforschung und -behandlung verwendet und wurde entwickelt, um psychologische Kernaspekte von Depression, Angst und Stress zu erfassen. Sie umfasst drei Skalen mit jeweils sieben Items. Die Erfassung psychischer Belastung hat einen zentralen Stellenwert in der Schmerzforschung und -behandlung. Für Depression als Komorbidität bei Schmerz bestehen dabei besondere methodische und konzeptionelle Schwierigkeiten. Reliabilität: Cronbachs Alpha lag bei Alpha = .91 (Depression), Alpha = .78-.82 (Angst) bzw. Alpha = .81-.89 (Stress). Validität: Konstruktvalidität des DASS wurden mit HADS (Hospital Anxiety and Depression Scale) und ADS (Allgemeine Depressionsskala) verglichen. Spezifität und Sensitivität für Depression wurden anhand eines strukturierten klinischen Interviews für DSM-IV (SKID) ermittelt und ebenfalls mit ADS und HADS verglichen. Nilges, P. & Essau, C. (2021). DASS. Depressions-Angst-Stress-Skalen - deutschsprachige Kurzfassung [Verfahrensdokumentation und Fragebogen mit Auswertung]. In Leibniz-Institut für Psychologie (ZPID) (Hrsg.), Open Test Archive. Trier: ZPID. https://doi.org/10.23668/psycharchives.4579 Disclaimer: After completion of my work with the measure, I will inform the test authors about the use of the measure and the results I have obtained by means of the feedback form.

Measurement Instrument Database for the Social Science (MIDSS) - The Pregnancy Related Beliefs Questionnaire (PRBQ)

- 30/09/20 - 1 modulo, 2 itemgroups, 54 elementi, 1 linguaggio

Itemgroups: Instructions, Belief

Moorhead, S. R. J., Owens, J., Scott, J. (2003). The Pregnancy Related Beliefs Questionnaire (PRBQ). Measurement Instrument Database for the Social Science. Retrieved 29.09.2020, from www.midss.ie Key references: Moorhead, S. R. J., Owens, J., and Scott, J. (2003). DEVELOPMENT AND PILOTING OF THE PREGNANCY RELATED BELIEFS QUESTIONNAIRE (PRBQ). Behavioural and Cognitive Psychotherapy, 31, 207-213. doi:10.1017/S1352465803002091 Primary use / Purpose: The Pregnancy Related Beliefs Questionnaire (PRBQ) is a 54-item inventory rated on 7 point Likert-type scale. Its purpose is to measure women’s' beliefs about pregnancy and make similar contributions as existing scales towards greater understanding and prediction of postnatal depression Background: Psychological measures have proven disappointing in the prediction of postnatal depression in women. To address this weakness, Moorhead, Owens, and Scott (2003) developed the Pregnancy Related Beliefs Questionnaire (PRBQ). The PRBQ was shown to correlate with several other constructs as measured by the Beck Depression Inventory (BDI), the Dysfunctional Attitude Scale, and the Cognitive Adaption to Stressful Events Questionnaire (CASE), as well as showing early potential in the prediction of postnatal depression. Psychometrics: The psychometric properties of the Pregnancy Related Beliefs Questionnaire (PRBQ) are discussed in Moorhead, Owens, and Scott (2003). Digital Object Identifier (DOI): http://dx.doi.org/10.13072/midss.323

Measurement Instrument Database for the Social Science (MIDSS) - Four-Dimensional Symptom Questionnaire (4DSQ)

- 12/08/20 - 1 modulo, 7 itemgroups, 50 elementi, 1 linguaggio

Itemgroups: Explanation, During THE PAST WEEK, did you suffer from:, During THE PAST WEEK, did you suffer from:, During THE PAST WEEK, did you feel:, During THE PAST WEEK, did you feel:, During THE PAST WEEK, did you:, During THE PAST WEEK:

Terluin, B.. (2012). Four-Dimensional Symptom Questionnaire (4DSQ) . Measurement Instrument Database for the Social Science. Retrieved 12.08.2020 from www.midss.ie Key references: Terluin B, Van Rhenen W, Schaufeli WB, De Haan M. The Four-Dimensional Symptom Questionnaire (4DSQ): measuring distress and other mental health problems in a working population. Work and Stress 2004; 18(3): 187-207. Terluin B, Van Marwijk HWJ, Adèr HJ, De Vet HCW, Penninx BWJH, Hermens MLM, Van Boeijen CA, Van Balkom AJLM, Van der Klink JJL, Stalman WAB. The Four-Dimensional Symptom Questionnaire (4DSQ): a validation study of a multidimensional self-report questionnaire to assess distress, depression, anxiety and somatization. BMC Psychiatry 2006; 6:34. Terluin B, Brouwers EPM, van Marwijk HWJ, Verhaak PFM, van der Horst HE. Detecting depressive and anxiety disorders in distressed patients in primary care; comparative diagnostic accuracy of the Four-Dimensional Symptom Questionnaire (4DSQ) and the Hospital Anxiety and Depression Scale (HADS). BMC Fam Pract 2009; 10:58. Primary use / Purpose: The 4DSQ is a self-report questionnaire to assess distress, depression, anxiety and somatization. It is mainly used in primary care. The 4DSQ helps to differentiate between normal distress and psychiatric disorder. Background: Many health care problems in primary care are stress-related (distress) and do not represent true psychiatric disorder (irrespective of whether DSM-IV criteria for depressive or anxiety disorders are fulfilled). Indiscriminate application of DSM-IV criteria in the primary care setting produces many false positive diagnoses confusing patients and misleading professionals. In health care practice the 4DSQ can be used to: - help patients acknowledge mental health issues when presenting with physical complaints, - assess the overall severity of the mental health problems, - detect depressive and anxiety disorders severe enough to require specific treatment (antidepressants or cognitive behavioral therapy), - monitor patients' progress under treatment. Psychometrics: The 4DSQ has been extensively tested for reliability and validity. Reliability is high (coefficients generally >.80). Factorial, critirion and concurrant validity has been confirmed. Web link to tool: Four-Dimensional Symptom Questionnaire (4DSQ) Other Information: The 4DSQ is free for non-commercial use. Available language versions: English, Dutch, French, German, Polish, Turkish Digital Object Identifier (DOI): http://dx.doi.org/10.13072/midss.167 Scoring: "no" = score 0 "sometimes" = score 1 "regularly" or more often = score 2 Distress: sum the items 17, 19, 20, 22, 25, 26, 29, 31, 32, 36, 37, 38, 39, 41, 47, 48 Interpretation: moderately elevated if > 10, strongly elevated if > 20 Depression: sum the items 28, 30, 33, 34, 35, 46 Interpretation: moderately elevated if > 2, strongly elevated if > 5 Anxiety: sum the items 18, 21, 23, 24, 27, 40, 42, 43, 44, 45, 49, 50 moderately elevated if > 8, strongly elevated if > 12 Somatisation: sum the items 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 moderately elevated if > 10, strongly elevated if > 20

Mood Disorder Questionnaire (MDQ)

- 26/08/20 - 1 modulo, 6 itemgroups, 19 elementi, 1 linguaggio

Itemgroups: Administrative, 1. Has there ever been a period of time when you were not your usual self and..., 2. If you checked YES to more than one of the above, have several of these ever happened during the same period of time? Please check 1 response only., 3. How much of a problem did any of these cause you — like being able to work; having family, money, or legal troubles; getting into arguments or fights? Please check 1 response only., 4. Have any of your blood relatives (i.e., children, siblings, parents, grandparents, aunts, uncles) had manic-depressive illness or bipolar disorder?, 5. Has a health professional ever told you that you have manic-depressive illness or bipolar disorder?

Author: Robert M. A. Hirschfeld, M.D., Department of Psychiatry and Behavioral Sciences, University of Texas Medical Branch, 1.302 Rebecca Sealy, 301 University Blvd., Galveston, TX 77555-0188 e-mail: ude.bmtu@hcsrihor Hirschfeld, Robert M. A.. “The Mood Disorder Questionnaire: A Simple, Patient-Rated Screening Instrument for Bipolar Disorder.” Primary care companion to the Journal of clinical psychiatry vol. 4,1 (2002): 9-11. doi:10.4088/pcc.v04n0104 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC314375/ [Titel anhand dieser PMC-ID in Citavi-Projekt übernehmen] #idm140485826533856title

PATIENT HEALTH QUESTIONNAIRE-9 - PATIENT HEALTH QUESTIONNAIRE-9 (PHQ-9)

- 20/09/21 - 1 modulo, 2 itemgroups, 10 elementi, 38 lingue

Itemgroups: Symptom frequency past 2 weeks, Problems with daily life activities

The Patient Health Questionnaire (PHQ) is a diagnostic tool for mental health disorders used by health care professionals that is quick and easy for patients to complete. In the mid-1990s, Robert L. Spitzer, MD, Janet B.W. Williams, DSW, and Kurt Kroenke, MD, and colleagues at Columbia University developed the Primary Care Evaluation of Mental Disorders (PRIME-MD), a diagnostic tool containing modules on 12 different mental health disorders. They worked in collaboration with researchers at the Regenstrief Institute at Indiana University and with the support of an educational grant from Pfizer Inc. During the development of PRIME-MD, Drs. Spitzer, Williams and Kroenke, created the PHQ and GAD-7 screeners. The PHQ-9, a tool specific to depression, simply scores each of the 9 DSM-IV criteria based on the mood module from the original PRIME-MD. ODM derived from http://www.phqscreeners.com/

PHQ-SADS

- 20/09/21 - 1 modulo, 6 itemgroups, 40 elementi, 1 linguaggio

Itemgroups: PHQ-SADS, Somatic symptoms past 4 weeks, Anxiety symptoms last two weeks, Anxiety attacks, Mood symptom frequency past 2 weeks, Problems with daily life activities

In the mid-1990s, Robert L. Spitzer, MD, Janet B.W. Williams, DSW, and Kurt Kroenke, MD, and colleagues at Columbia University developed the Primary Care Evaluation of Mental Disorders (PRIME-MD), a diagnostic tool containing modules on 12 different mental health disorders. They worked in collaboration with researchers at the Regenstrief Institute at Indiana University and with the support of an educational grant from Pfizer Inc. During the development of PRIME-MD, Drs. Spitzer, Williams and Kroenke, created the PHQ and GAD-7 screeners. The PHQ-SADS consists of the following parts of the PHQ: the depression scale (or the PHQ-9), the somatic symptom scale (or the PHQ-15), the questions about anxiety (part 3 in the original PHQ) and a question about overall daily functioning (part 11 in the original PHQ). Additionally, it contains the GAD-7, a brief questionnaire which scores seven common anxiety symptoms. ODM derived from http://www.phqscreeners.com/.

Effects of D3 antagonist GSK598809 on neural and behavioural responses to food reward/reinforcement after a single dose in overweight/obese subjects NCT01039454 - Questionnaire Checklist (Sessions 1+2)

- 09/07/18 - 1 modulo, 4 itemgroups, 26 elementi, 1 linguaggio

Itemgroups: Administrative Data, Pre-Dose and 2h post-Dose Questionnaires, 4 and 10 h post-Dose Questionnaire, 5, (8), 24 hrs post-Dose questionnaires

This ODM file contains a checklist for Completion of Questionnaires to be filled at the mentioned times during Session visits 1 and 2 (Day 1 each). Study ID: 109710 Clinical Study ID: DAN109710 Study Title: A single-blind, randomized, placebo controlled, two-period crossover fMRI study to investigate the effects of the D3 antagonist GSK598809 on neural and behavioural responses to food reward and reinforcement after a single oral dose of GSK598809 in overweight and obese subjects. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01039454 https://clinicaltrials.gov/ct2/show/NCT01039454 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: GSK598809 Trade Name: Study Indication: Substance Dependence Brief Summary: This novel compound is a new experimental treatment that may help people to stop compulsive overeating. Compulsive overeating or binge eating is one of the main reasons why people are overweight or obese. Recent research has shown that some kinds of overeating may be linked to a brain chemical called dopamine. There is some evidence that blocking the action of this chemical in animals can reduce food intake, particularly of foods that are high in fat and sugar. The purpose of this study is to find out if this compound (which blocks the effects of dopamine) has the same effect in overweight or obese people, as it does in animals.

Effects of D3 antagonist GSK598809 on neural and behavioural responses to food reward/reinforcement after a single dose in overweight/obese subjects NCT01039454 - Questionnaire Checklist (Early Withdrawal, Follow-up, 12 Week Follow-up)

- 27/06/18 - 1 modulo, 2 itemgroups, 9 elementi, 1 linguaggio

Itemgroups: Administrative Data, Questionnaires

This ODM file contains a checklist for Completion of Questionnaires to be filled at Early withdrawal, Follow-up and Part B/12-Week Follow-up. Study ID: 109710 Clinical Study ID: DAN109710 Study Title: A single-blind, randomized, placebo controlled, two-period crossover fMRI study to investigate the effects of the D3 antagonist GSK598809 on neural and behavioural responses to food reward and reinforcement after a single oral dose of GSK598809 in overweight and obese subjects. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01039454 https://clinicaltrials.gov/ct2/show/NCT01039454 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: GSK598809 Trade Name: Study Indication: Substance Dependence Brief Summary: This novel compound is a new experimental treatment that may help people to stop compulsive overeating. Compulsive overeating or binge eating is one of the main reasons why people are overweight or obese. Recent research has shown that some kinds of overeating may be linked to a brain chemical called dopamine. There is some evidence that blocking the action of this chemical in animals can reduce food intake, particularly of foods that are high in fat and sugar. The purpose of this study is to find out if this compound (which blocks the effects of dopamine) has the same effect in overweight or obese people, as it does in animals.

Effects of D3 antagonist GSK598809 on neural and behavioural responses to food reward/reinforcement after a single dose in overweight/obese subjects NCT01039454 - Questionnaire Checklist (Screening)

- 09/07/18 - 1 modulo, 2 itemgroups, 18 elementi, 1 linguaggio

Itemgroups: Administrative Data, Questionnaires at Screening

This ODM file contains a checklist for Completion of Questionnaires for the Screening Visit. Study ID: 109710 Clinical Study ID: DAN109710 Study Title: A single-blind, randomized, placebo controlled, two-period crossover fMRI study to investigate the effects of the D3 antagonist GSK598809 on neural and behavioural responses to food reward and reinforcement after a single oral dose of GSK598809 in overweight and obese subjects. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01039454 https://clinicaltrials.gov/ct2/show/NCT01039454 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: GSK598809 Trade Name: Study Indication: Substance Dependence Brief Summary: This novel compound is a new experimental treatment that may help people to stop compulsive overeating. Compulsive overeating or binge eating is one of the main reasons why people are overweight or obese. Recent research has shown that some kinds of overeating may be linked to a brain chemical called dopamine. There is some evidence that blocking the action of this chemical in animals can reduce food intake, particularly of foods that are high in fat and sugar. The purpose of this study is to find out if this compound (which blocks the effects of dopamine) has the same effect in overweight or obese people, as it does in animals.

Measurement Instrument Database for the Social Science (MIDSS) - Metereopathy Questionnaire (METEO-Q)

- 17/09/21 - 1 modulo, 3 itemgroups, 42 elementi, 1 linguaggio

Itemgroups: General Information, Meteoropathy Questionnaire, Meteoropathy Checklist

Mazza, M., Di Nicola, M., Janiri, L. (2012). Metereopathy Questionnaire (METEO-Q). Measurement Instrument Database for the Social Science. Retrieved 04.09.2020, from www.midss.ie Key references: Mazza, M., Di Nicola, M., Catalano, V., Callea, A., Martinotti, G., Harnic, D., Bruschi, A., Battaglia, C., Janiri, L. (2012). Description and validation of a questionnaire for the detection of meteoropathy and meteorosensitivity: the METEO-Q. Comparative Psychiatry, 53(1), 103-106. Primary use / Purpose: To detect meteoropathy and meteorosensitivity (effects of weather changes) on both healthy and psychiatric individuals Background: The term meteoropathy derives from the Greek ‘meteora’ (things high in the air or celestial phenomena) and ‘pathos’ (illness, suffering, pain), and it is used to indicate every pathological dimension in some way related to weather conditions. This concept is referred to a set of temperature, humidity, barometric pressure and brightness. Meteoropathy can be considered a syndrome: in fact, it is represented by a group of symptoms and pathological reactions that manifest when there is a gradual or sudden change in one or more meteorological factors in a given area. Scientists claimed that middle aged persons, especially women are at greater risk of becoming meteoropathic, but even children are at risk. The most frequent symptoms are represented by an increase in depression, both mental and physical, weakness, hypertension, cephalea, a desire to remain indoors, increased susceptibility to pain in the joints and muscles, difficulty in breathing and a heavy feeling in the stomach. There may also be mood disturbances, irritability and symptoms in the cardiovascular system, such as palpitations or pain in the sternum. These symptoms last for one or two days. They begin to decrease once the weather has changed, but return if the weather changes again. When the changes follow one after another, the symptoms decrease in intensity each time, as a sort of adapting process occurs. There is a quantitative difference between the terms ‘meteorosensitivity’ and ‘meteoropathy’. Meteorosensitive are people biologically susceptible to feel the effect of particular atmospherical events on mind and body; meteoropathic are those individuals who develop a specific illness or a worsening of the existing diseases as a consequence of these climatic changes. The Metereopathy Questionnaire (METEO-Q) is a self-administered questionnaire for the detection of meteoropathy and meteorosensitivity. This is believed to be the first questionnaire designed to measure symptoms of meteoropathy. Psychometrics: The METEO-Q has been formulated to assess the sensitivity to climate changes and their impact on symptomatologic modifications. It consists in 11 items and a structured checklist aiming to identify the physical and psychological symptoms mainly related to climate variations. Items 1-5 quantitatively explore variation of mood related or caused by specific weather conditions (variations of mood in relation to the change of latitude; variations of mood in relation to atmospheric changes; variations of mood in relation to the brightness of the sky; variations of mood caused by the temperature changes; mood changes caused by the seasons changing), while items 6-11 explore qualitative effects of symptoms (degree of relation between symptomatology and the climatic change; tendency of disturbs to minimize or disappear when the triggering condition stops or when an opposite environmental condition comes up; eventual coincidence of these disturbs with other cyclical phenomena; presence of prodromical symptoms; interference with daily activities; uneasiness feelings induced by climatic changes). The checklist explores most frequently experienced disturbs related to climatic, atmospheric, temperature or brightness changes. For each of the 21 symptoms, individuals are asked to rate on the basis of a 5-point Likert scale rating from 0 (absent) to 4 (severe). Digital Object Identifier (DOI): http://dx.doi.org/10.13072/midss.269

DELCODE: DZNE – Longitudinal Cognitive Impairment and Dementia Study - Geriatric Depression Scale (GDS), Geriatric Anxiety Inventory – Short Form (GAI‐SF) (Geriatrische Depressionsskala (GDS) und GAI-SF)

- 14/04/20 - 1 modulo, 3 itemgroups, 21 elementi, 1 linguaggio

Itemgroups: Administrative Data, Geriatric Depression Scale (GDS), Geriatric Anxiety Inventory – Short Form (GAI‐SF)

DELCODE is conducted by DZNE, the German Center for Neurodegenerative Diseases within the Helmholtz Association. The following information was taken from https://www.dzne.de/en/research/studies/clinical-studies/delcode/. Background and aims: One of the important aims of research into Alzheimer's is to find ways of detecting the disease early – if at all possible, as soon as the first minor symptoms appear, or even before any symptoms at all have appeared. Such detection capabilities are the necessary basis for development of therapies that can be applied at such early stages in the disease. Recent research indicates that such therapies could be more effective than therapies initiated during the disease's later stages. Over a period of several years, the DELCODE study is studying persons in early stages of the disease, along with various risk groups. The research is aimed at the development of procedures for characterizing early stages of the disease, at improving prediction of the course of the disease and at identifying new markers for early diagnosis of Alzheimer's-related dementia. Overview: DELCODE is set up to run for an initial period of three years, and to include a total of 1,000 study participants, who will be examined on a yearly basis. The group of participants will include persons with no complaints (healthy control subjects), patients with slight memory impairment or mild dementia and first-degree relatives of patients with diagnosed Alzheimer's disease. The minimum age for participants is 60. Course of the study: The examinations in the framework of the study will include a comprehensive interview carried out by a study investigator, a detailed neuropsychological examination (testing of memory functions and other areas of cognitive performance), a blood test and a cranial MRI scan. Optionally, subject to the study participant's consent in each case, a lumbar puncture (collection of cerebrospinal fluid) will be carried out." For more information (e.g. principle investigator and study coordination), please visit the above link or https://www.dzne.de. This document contains the Geriatric Depression Scale (GDS) and the Geriatric Anxiety Inventory – Short Form (GAI‐SF). It has to be filled in for Baseline and for all Follow-ups. For use of the questionnaire GDS no licence is required. For more information to the GDS see Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, Leirer VO. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1982-83;17(1):37-49. Due to potential copyright on the questionnaire GAI-SF included in the DZNE DELCODE protocol, GAI-SF will only be included as text result item in this version of the DELCODE forms (at least until permission to publish is received from the original authors or becomes clear upon further research). The respective score items will have a comment in their descriptions about this to distinguish them from score items that were already defined like that by DZNE. For more information to GAI-SF see: Pachana, N., Byrne, G., Siddle, H., Koloski, N., Harley, E., & Arnold, E. (2007). Development and validation of the Geriatric Anxiety Inventory. International Psychogeriatrics, 19, 103-114. doi: 10.1017/S1041610206003504. Rozzini, L., Chilovi, B., Peli, M., Conti, M., Rozzini, R., Trabucchi, M., Padovani, A. (2009). Anxiety symptoms in mild cognitive impairment. International Journal of Geriatric Psychiatry, 24, 300-305. doi: 10.1002/gps.2106.

PSS-14

- 09/02/21 - 1 modulo, 1 ItemGroup, 14 elementi, 9 lingue

ItemGroup: PSS-14

ODM derived from https://www.cmu.edu/dietrich/psychology/stress-immunity-disease-lab/scales/index.html. Cohen S, Kamarck T, Mermelstein R: A global measure of perceived stress. J Health Human Behav 1983, 24:385-396. ; Cohen, S., & Williamson, G. (1988). Perceived stress in a probability sample of the U.S. In S. Spacapam & S. Oskamp (Eds.), The social psychology of health: Claremont Symposium on Applied Social Psychology. Newbury Park, CA: Sage. (provides NORMATIVE DATA for the PSS-4, PSS-10, and PSS-14 from a large U.S. sample polled in 1983); Cohen, S., Kamarck, T., & Mermelstein, R. (1983). A global measure of perceived stress. Journal of Health and Social Behavior, 24, 385-396. (provides RELIABILITY and VALIDITY); Hewitt, P. L., Flett, G. L., & Mosher, S. W. (1992). The perceived stress scale: Factor structure and relation to depression symptoms in a psychiatric sample. Journal of Psychopathology and Behavioral Assessment, 14(3), 247-257. Bulgarian version: Permission granted by Vihra Naydenova. Chilean Spanish version: Tapia, D., Cruz, C., Gallardo, I., & Dasso, M. (2007). Adaptacion de la Escala de Percepcion Global de Estres (EPGE) en estudiantes adultos de escasos recursos en Santiago, Chile. Psiquiatria y Salud Mental, 24, 109-119. Permission granted by Dr. Carlos Cruz Marin. French version: Rolland, J.P. (1999). Du stress au bien-être subjectif. proposition d'une approche intégrative. Habilitation à diriger les recherches, Université Paris X Nanterre. Hungarian version: Stauder, A., & Konkolÿ Thege, B. (2006). Az Észlelt Stressz Kérdőív (PSS) magyar verziójának jellemzői [Characteristics of the Hungarian version of the Perceived Stress Scale (PSS)]. Mentálhigiéné és Pszichoszomatika, 7, 203-216. Swedish version: Permission granted by Dr. Ingibjörg Jonsdottir. European Spanish version: Remor, E. (2006). Psychometric Properties of a European Spanish Version of the Perceived Stress Scale (PSS). The Spanish Journal of Psychology, 9 (1), 86-93. Turkish version: Yerlikaya, E. E. & İnanç, B. (2007), Psychometric Properties of the Turkish Translation of the Perceived Stress Scale (PSS), 9th National Congress of Psychological Counseling and Guidance, 17-19 October, İzmir. Mexican Spanish version: Permission granted by Dr. Mónica Teresa González Ramírez.

Keywords

Sommario

Modelli di dati selezionati

DASS Depressions-Angst-Stress-Skalen – deutschsprachige Kurzfassung - DASS

Measurement Instrument Database for the Social Science (MIDSS) - The Pregnancy Related Beliefs Questionnaire (PRBQ)

Measurement Instrument Database for the Social Science (MIDSS) - Four-Dimensional Symptom Questionnaire (4DSQ)

Mood Disorder Questionnaire (MDQ)

PATIENT HEALTH QUESTIONNAIRE-9 - PATIENT HEALTH QUESTIONNAIRE-9 (PHQ-9)

PHQ-SADS

Effects of D3 antagonist GSK598809 on neural and behavioural responses to food reward/reinforcement after a single dose in overweight/obese subjects NCT01039454 - Questionnaire Checklist (Sessions 1+2)

Effects of D3 antagonist GSK598809 on neural and behavioural responses to food reward/reinforcement after a single dose in overweight/obese subjects NCT01039454 - Questionnaire Checklist (Early Withdrawal, Follow-up, 12 Week Follow-up)

Effects of D3 antagonist GSK598809 on neural and behavioural responses to food reward/reinforcement after a single dose in overweight/obese subjects NCT01039454 - Questionnaire Checklist (Screening)

Measurement Instrument Database for the Social Science (MIDSS) - Metereopathy Questionnaire (METEO-Q)

DELCODE: DZNE – Longitudinal Cognitive Impairment and Dementia Study - Geriatric Depression Scale (GDS), Geriatric Anxiety Inventory – Short Form (GAI‐SF) (Geriatrische Depressionsskala (GDS) und GAI-SF)

PSS-14

Keywords

Sommario

Modelli di dati selezionati

Contatto

Aiuto